Final full-cohort analysis of phase III THOR (278 patients, FGFR3/2-altered metastatic urothelial carcinoma after anti-PD-(L)1): erdafitinib vs docetaxel or vinflunine gave median OS 12.1 vs 8.7 months (HR 0.65); grade 3–4 adverse events 67.6% vs 65.8%.
RCTn = 278
Loriot et al. Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma